Monday, July 9, 2018

KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints - Benzinga


Benzinga

KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints
Benzinga
KemPharm Inc (NASDAQ: KMPH) shares plunged nearly 7 percent off Monday's open despite news that its KP415 candidate for ADHD met primary and secondary endpoints in a pivotal efficacy and safety trial.
KemPharm shoots for ADHD filling in 2019BioPharma Dive
KemPharm's KP415 successful in late-stage ADHD study; shares ahead 7% premarketSeeking Alpha
KemPharm Dips Despite Positive ADHD Trial Results24/7 Wall St.
GlobeNewswire (press release)
all 13 news articles »

No comments:

Post a Comment